Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02383212 · ClinicalTrials.gov registry record · Phase 1
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A Phase 1 study of Advanced Cancer and Advanced Malignancies, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 398
- Enrollment target
- 20
- Study locations
NCT02383212: Completed Phase 1 study of Advanced Cancer and Advanced Malignancies, sponsored by Regeneron Pharmaceuticals.
NCT02383212 is a Phase 1 study of Advanced Cancer and Advanced Malignancies that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 398 participants, above the 243-participant average among 122 other Advanced Cancer trials with a reported enrollment target (64% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02383212, a Phase 1 study of Advanced Cancer and Advanced Malignancies, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 398 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.
Primary Outcome
Primary safety variables include incidence and severity of TEAEs, abnormal laboratory findings and number of participants with dose limiting toxicities (DLTs)
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Cemiplimab
- RADIATION Hypofractionated radiotherapy
Study Locations (20)
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Western Regional Medical Center - Goodyear
- Mayo Clinic - Phoenix
- University of Arizona Cancer Center - Tucson
California
- City of Hope National Medical Center - Duarte
- The Angeles Clinic and Research Institute - Los Angeles
- Ronald Reagan UCLA Medical Center - Los Angeles
- Stanford University - Stanford
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Connecticut
- Norwalk Hospital - Norwalk
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Florida
- H Lee Moffitt Cancer Center and Research Institute - Tampa
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 398 participants |
| Start Date | 2015-02-02 |
| Est. Completion | 2019-11-18 |
| Phase | Phase 1 |
What the finished NCT02383212 record still lists
NCT02383212 is an interventional study that assigns participants to a tested intervention. The registered 398 participants enrollment target is mid-sized for trials with a published cap, above the 243-participant average among 122 other Advanced Cancer trials with a reported enrollment target (64% higher).
The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02383212 names 20 study sites across 14 states, led by Arizona, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02383212 about?
NCT02383212 is a clinical study titled "Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies". This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.
What is the current status of trial NCT02383212?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 398 participants. The study started on 2015-02-02. Estimated completion is 2019-11-18.
What conditions does trial NCT02383212 study?
This clinical trial studies the following conditions: Advanced Cancer, Advanced Malignancies.
What interventions are being tested in trial NCT02383212?
The interventions under investigation include: Cyclophosphamide (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), Cemiplimab (DRUG), Hypofractionated radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT02383212?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02383212 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02383212's enrollment target sits among peer trials
398 14th of 122 higher than 109 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05365581 · 398 participants · Phase 1
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- NCT03165734 · 399 participants · Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- NCT05022862 · 399 participants · NA
Economic Incentives and vDOT for Latent Tuberculosis Infection
- NCT00601939 · 397 participants · NA
Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI